Optomed Oyj : Interim Report, January – March 2026, presentation

About this update from Optomed Oyj Class A

‌Optomed Q1 2026 6 th May 2026 Juho Himberg, CEO Sakari Knuutti, CFO ‌Highlights Q1 1. Strongest quarter ever for Aurora AEYE new subscription sales 2. Weak quarter in terms of revenue development 3. Temporary uncertainty regarding CMS proposal to remove the diabetic eye exam from the HEDIS Star Rating during the quarter ‌Q1-2026 Key Figures EBITDA IMPROVED IN SPITE OF LOWER REVENUE Q1/2026 Q1/2025 Change Revenue 3,351 4,021 -16.7% Gross profit 2,302 2,693 -14.5% Gross margin 68.7% 67.0% +1.7pp EBITDA -701 -737 4.9% EBITDA margin -20.9% -18.3% -2.6pp Net profit / loss -1,101 -1,581 30.4% Earnings per share -0.05 -0.08 34.2% Cash flow from operating activities -1,432 371 -485.5% ‌Segment highlights ‌Devices Segment Q1-2026 GOOD AURORA AEYE PERFORMANCE BUT WEAKER CAPITAL SALES 1. Q1/2026 Q1/2025 Change Revenue 1,065 1,526 -30.2% Gross profit 668 897 -25.6% Gross margin 62.7% 58.8% +3.9pp EBITDA -348 -297 -17.0% EBITDA margin -32.7% -19.5% -13.2pp Optomed USA continued to grow during the quarter, driven by Aurora AEYE 2. Capex sales affected by HEDIS uncertainty during the quarter 3. Margins improved supported by Aurora AEYE ‌Software Segment Q1-2026 SOFTWARE EBITDA NORMALIZED 1. Q1/2026 Q1/2025 Change Revenue 2,285 2,496 -8.4% Gross profit 1,634 1,796 -9.0% Gross margin 71.5% 72.0% -0.4pp EBITDA 477 521 -8.5% EBITDA margin 20.9% 20.9% 0.0pp Modest revenue decline primarily due to timing effects of various software deliveries 2. The EBITDA margin stabilized at 20.9% following Q4 2025, which was affected by one-off costs 3. General IT consulting market conditions in Finland remained weak ‌Strategic Progress CONTINUOUS PROGRESS 1. Aurora AEYE continues to perform: Strongest quarter ever for Aurora AEYE new subscription sales 2. The collaboration with a global top-10 pharma company progressed with the ESG reporting capabilities build-up 3. China: joint venture continues to develop while it remains a binary opportunity ‌Cash Flow Q1-2026 Q1 2026 Q1 2025 Loss for the financial year -1,101 -1,581 Cash flows before change in net working capital -541 -692 Change in net working capital -887 1,101 Cash flows before finance items -1,429 410 Cash flows from finance items -3 -38 Net cash from operating activities -1,432 371 Net cash used in investing activities -503 -781 Net cash from financing activities -244 -357 Net increase (decrease) in cash and cash equivalents -2,179 -767 Cash and cash equivalents at the beginning of period 9,909 10,467 Cash and cash equivalents at end of period 7,752 9,688 CASH POSITION AT EUR 7.8 MILLION Cash flows before change in net working capital improved in spite of weakened revenue Working capital outflows reduced net cash from operating activities Cash position at EUR 7.8 million (12.1) ‌Outlook 2026 OPTOMED EXPECTS ITS FULL YEAR 2026 REVENUE TO GROW COMPARED TO 2025 Key items supporting our growth: Strongest quarter ever for Aurora AEYE new subscription sales and growing recurring revenue base Lumo sales on-going AI clearance as a quality stamp seems to drive also our traditional camera sales in the US Areas of uncertainty and pressure on growth: Software segment growth facing a difficult domestic market environment in Finland Weak Q1 puts pressure on Q2-4 Challenges to accurately forecast the timing and size of large capital expenditure deals due to various uncertainties and market dynamics Geopolitics and FOREX ‌Q1-2026 in summary Devices revenue growth affected by timing issues and regulatory uncertainty during the quarter Software segment margins normalized while revenue growth was affected by timing effects Temporary uncertainty regarding CMS proposal to remove the diabetic eye exam from the HEDIS Star Rating during the quarter Strongest quarter ever for Aurora AEYE new subscription sales ‌Appendix 31 March 2026 31 March 2025 ASSETS Goodwill 4,256 4,256 Development costs 8,670 8,487 Other intangible assets 1,009 1,323 Total intangible assets 13,935 14,066 Total tangible assets 1,028 857 Total non-current assets 16,104 16,318 Inventories 2,781 1,713 Trade and other receivables 3,347 3,046 Cash and cash equivalents 7,752 9,688 Total current assets 13,880 14,447 TOTAL ASSETS 29,985 30,765 LIABILITIES Total equity 22,717 22,470 Non-current liabilities 1,731 2,243 Total current liabilities 5,536 6,052 TOTAL EQUITY AND LIABILITIES 29,985 30,765 ‌Balance Sheet Equity ratio of 75.8 (73.0) percent Total borrowings of EUR 1.3 (2.1) million Net working capital was EUR 1,514 (188) Interest-bearing net debt totaled EUR -6,430 (-7,621) thousand.

View stock analysis, news, and events for Optomed Oyj Class A